Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19

Conclusion Our data support EID of ocrelizumab as potential risk mitigation strategy in times of the COVID-19 pandemic. Classification of Evidence This study provides Class IV evidence that for patients with RRMS, an EID of at least 4 weeks does not diminish effectiveness of ocrelizumab.

http://nn.neurology.org/cgi/content/short/8/5/e1035?rss=1

Source: Neurology Neuroimmunology and Neuroinflammation - July 14, 2021 Category: Neurology Authors: Rolfes, L., Pawlitzki, M., Pfeuffer, S., Nelke, C., Lux, A., Pul, R., Kleinschnitz, C., Kleinschnitz, K., Rogall, R., Pape, K., Bittner, S., Zipp, F., Warnke, C., Goereci, Y., Schroeter, M., Ingwersen, J., Aktas, O., Klotz, L., Ruck, T., Wiendl, H., Meuth Tags: MRI, Clinical trials Observational study (Cohort, Case control), COVID-19, Multiple sclerosis Article Source Type: research